Rigel (United States)

Recent papers from Rigel (United States)

1. A Microsatellite Accommodation Canister (MAC) for Electromagnetic Lunar Launch and Orbital Deployment2026
2. A Machine Learning Framework for Identifying and Detecting Potentially Habitable Exomoons Around Sub-Neptunian Planets2026
3. Clinical factors driving use of RET inhibitor pralsetinib and associated real-world outcomes in RET fusion–positive NSCLC: A retrospective chart review.Journal of Clinical Oncology · 2026
4. Real-world treatment patterns and outcomes with olutasidenib after venetoclax in IDH1 -mutated AML using EHR data.Journal of Clinical Oncology · 2026
5. Treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using real-world data from a chart review.Journal of Clinical Oncology · 2026
6. Evaluating the cost per month of response for olutasidenib (OLU) versus ivosidenib (IVO) for patients with relapsed/refractory (R/R) mutant IDH1 (m IDH1 ) acute myeloid leukemia (AML).Journal of Clinical Oncology · 2026
7. Efficacy and safety of pralsetinib in RET fusion–positive solid tumors: Data from the TAPISTRY trial.Journal of Clinical Oncology · 2026
8. Association of acute myeloid leukemia (AML) patient, disease, and molecular characteristics with a long-term (LT) response to olutasidenib.Journal of Clinical Oncology · 2026
9. Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.Journal of Clinical Oncology · 2026
10. Efficacy and safety of pralsetinib in advanced or metastatic RET -altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.Journal of Clinical Oncology · 2026
11. Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor.2026
12. Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trialNature Communications · 2026
13. Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Data from the TAPISTRY trial.Journal of Clinical Oncology · 2026
14. Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohortJournal of Hematology & Oncology · 2025
15. Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohortJournal of Hematology & Oncology · 2025
16. Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control armLeukemia & lymphoma/Leukemia and lymphoma · 2025
17. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trialJournal of Hematology & Oncology · 2025
18. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmBritish Journal of Haematology · 2024
19. Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid LeukemiaCurrent Treatment Options in Oncology · 2024
20. CH-related Mutant ASXL1 Promotes Atherosclerosis in Mice via Dysregulated Innate Immunity2024